Sara M Tolaney

Author PubWeight™ 0.75^‹?›

Rank	Title	Journal	Year	PubWeight™‹?›
1	A phase 1 study combining the HER3 antibody seribantumab (MM-121) and cetuximab with and without irinotecan.	Invest New Drugs	2016	0.75